Printer Friendly

Men Put off Enlarged Prostate Treatment Due to Fear of Impotence, Ejaculation Problems, Finds Study.

M2 PHARMA-June 15, 2015-Men Put off Enlarged Prostate Treatment Due to Fear of Impotence, Ejaculation Problems, Finds Study

(C)2015 M2 COMMUNICATIONS

A survey commissioned by UK-based medical device maker NeoTract, Inc. has revealed that 42% of British men aged 50+ say they would delay treatment if diagnosed with an enlarged prostate due to a high risk of impotence (erectile dysfunction) caused by surgery and or drug therapy, the company said on Monday.

In all, 41% would not have surgery or take medication due to a risk of conventional treatments causing incontinence.

The independently conducted poll of 1,000 British men aged over 50 shows that 11% of the men surveyed have already been diagnosed with Benign Prostatic Hyperplasia, an enlargement of the prostate gland, and who therefore may be living with considerable symptoms such as frequent and urgent urination and slow emptying.

Up to 40% of all men over the age of 50 eventually develop the condition.Since reaching the age of 50, around half of the respondents feel their sex drive has remained the same as when they were younger.

The average man aged over 50 has sex once a week; but half would like to be having more sex than they currently do.

Neil Barber, Consultant Urologist at Frimley Park Hospital in Surrey, explains why a delay in treating BPH means that men have to not only put up with symptoms that negatively effect their quality of life but also run the risk of those symptoms deteriorating over time or suddenly being unable to pass urine, a very painful and unpleasant experience.

Yet many men diagnosed with BPH may be eligible for a new surgical treatment that preserves sexual function and carries low risk of incontinence.

According to NeoTract, patients receiving the company's UroLift System Treatment report rapid symptomatic improvement, an even more rapid return to normal activities including work, and complete preservation of sexual function.

Most common adverse events reported were mild and transient such as bleeding and soreness.

BPH, also known as enlarged prostate, is a medical condition in which the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. The condition is common, affecting approximately 500 million men worldwide.

The UroLift System is available in the US, Europe, Australia and Canada.

NeoTract is focused on developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 15, 2015
Words:419
Previous Article:Spineguard Raises EUR 2.8m from Share Sale.
Next Article:InSite Vision Incorporated completes New Drug Application for BromSite.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters